JP2020515234A5 - - Google Patents

Download PDF

Info

Publication number
JP2020515234A5
JP2020515234A5 JP2019536901A JP2019536901A JP2020515234A5 JP 2020515234 A5 JP2020515234 A5 JP 2020515234A5 JP 2019536901 A JP2019536901 A JP 2019536901A JP 2019536901 A JP2019536901 A JP 2019536901A JP 2020515234 A5 JP2020515234 A5 JP 2020515234A5
Authority
JP
Japan
Prior art keywords
seq
composition
sequence
sequence identity
pbmc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019536901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515234A (ja
JP7260170B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012998 external-priority patent/WO2018129540A1/en
Publication of JP2020515234A publication Critical patent/JP2020515234A/ja
Publication of JP2020515234A5 publication Critical patent/JP2020515234A5/ja
Priority to JP2022189475A priority Critical patent/JP2023015407A/ja
Application granted granted Critical
Publication of JP7260170B2 publication Critical patent/JP7260170B2/ja
Priority to JP2025051839A priority patent/JP2025098175A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2019536901A 2017-01-09 2018-01-09 事前の免疫化ステップのないｈｉｖ免疫療法 Active JP7260170B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022189475A JP2023015407A (ja) 2017-01-09 2022-11-28 事前の免疫化ステップのないｈｉｖ免疫療法
JP2025051839A JP2025098175A (ja) 2017-01-09 2025-03-26 事前の免疫化ステップのないｈｉｖ免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444147P 2017-01-09 2017-01-09
US62/444,147 2017-01-09
PCT/US2018/012998 WO2018129540A1 (en) 2017-01-09 2018-01-09 Hiv immunotherapy with no pre-immunization step

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022189475A Division JP2023015407A (ja) 2017-01-09 2022-11-28 事前の免疫化ステップのないｈｉｖ免疫療法

Publications (3)

Publication Number Publication Date
JP2020515234A JP2020515234A (ja) 2020-05-28
JP2020515234A5 true JP2020515234A5 (https=) 2021-10-07
JP7260170B2 JP7260170B2 (ja) 2023-04-18

Family

ID=62790837

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019536901A Active JP7260170B2 (ja) 2017-01-09 2018-01-09 事前の免疫化ステップのないｈｉｖ免疫療法
JP2022189475A Withdrawn JP2023015407A (ja) 2017-01-09 2022-11-28 事前の免疫化ステップのないｈｉｖ免疫療法
JP2025051839A Pending JP2025098175A (ja) 2017-01-09 2025-03-26 事前の免疫化ステップのないｈｉｖ免疫療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022189475A Withdrawn JP2023015407A (ja) 2017-01-09 2022-11-28 事前の免疫化ステップのないｈｉｖ免疫療法
JP2025051839A Pending JP2025098175A (ja) 2017-01-09 2025-03-26 事前の免疫化ステップのないｈｉｖ免疫療法

Country Status (10)

Country Link
US (1) US20200384021A1 (https=)
EP (1) EP3565564A4 (https=)
JP (3) JP7260170B2 (https=)
KR (3) KR20240023703A (https=)
CN (2) CN118931843A (https=)
AU (2) AU2018205388A1 (https=)
BR (1) BR112019014082A2 (https=)
CA (1) CA3048643A1 (https=)
IL (1) IL267794A (https=)
WO (1) WO2018129540A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
CN116064678A (zh) 2016-01-15 2023-05-05 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
WO2017156311A2 (en) 2016-03-09 2017-09-14 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
JP2020524996A (ja) 2017-06-16 2020-08-27 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
KR20200135852A (ko) * 2018-03-27 2020-12-03 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 유전자 변형 림프구의 제조 방법
WO2021178571A1 (en) * 2020-03-03 2021-09-10 American Gene Technologies International Inc. On demand expression of exogenous factors in lymphocytes to treat hiv
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
JP2024110682A (ja) 2023-02-03 2024-08-16 帝人株式会社 ポリオレフィン微多孔膜

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT904392E (pt) * 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
RU2305708C2 (ru) * 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
CN1738648A (zh) * 2003-01-17 2006-02-22 佛罗里达大学研究基金会有限公司 小干扰rna基因治疗
WO2005028634A2 (en) 2003-09-18 2005-03-31 Emory University Improved mva vaccines
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
WO2010051521A1 (en) * 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection
EP2191834A1 (en) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Compositions and methods for treating retrovirus infections
WO2010127166A2 (en) 2009-04-30 2010-11-04 The Regents Of The University Of California Combination anti-hiv vectors, targeting vectors, and methods of use
ES2657737T3 (es) 2009-07-15 2018-03-06 Calimmune Inc. Vector dual para la inhibición del virus de la inmunodeficiencia humana
WO2011103417A2 (en) * 2010-02-18 2011-08-25 Emory University Of Technology Transfer Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
CN107405357B (zh) * 2014-10-14 2021-12-31 德克萨斯科技大学系统 多重shRNAs及其应用
EP3319631A4 (en) * 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
WO2017139065A1 (en) * 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
AU2017292582C1 (en) * 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy

Similar Documents

Publication Publication Date Title
JP2020515234A5 (https=)
US20240252615A1 (en) Pre-immunization and immunotherapy
Guo et al. Interferon resistance of emerging SARS-CoV-2 variants
JP7162895B2 (ja) Ｈｉｖ予備免疫化および免疫療法
Perron et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis
Narasipura et al. Role of β-catenin and TCF/LEF family members in transcriptional activity of HIV in astrocytes
JP2019525914A5 (https=)
Zhou et al. SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans
JP2022166288A5 (https=)
JP2022101658A5 (https=)
JP2019509029A5 (https=)
Matsuura et al. Neuroimmunity of HTLV-I infection
BR112019014082A2 (pt) Imunoterapia para hiv sem etapa de pré-imunização
CN103184224A (zh) 一种抗艾滋病病毒感染的三联miRNA及构建方法
Breed et al. Elite control, gut CD4 T cell sparing, and enhanced mucosal T cell responses in Macaca nemestrina infected by a simian immunodeficiency virus lacking a gp41 trafficking motif
WO2019191314A1 (en) Methods of manufacturing genetically-modified lymphocytes
Wang et al. Characterization of equine infectious anemia virus long terminal repeat quasispecies in vitro and in vivo
Li et al. Effect of HIV-1 Tat on Secretion of TNF-α and IL-1β by U87 Cells in AIDS Patients with or without AIDS Dementia Complex
Berry et al. Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8)
Dash et al. Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection
Calonge et al. Different expression of interferon-stimulated genes in response to HIV-1 infection in dendritic cells based on their maturation state
Johnson et al. Identification of European bat lyssavirus isolates with short genomic insertions
Nüesch et al. Proteins specifically binding to the 3′ untranslated region of hepatitis A virus RNA in persistently infected cells
Kusagawa et al. Isolation and characterization of a full-length molecular DNA clone of Ghanaian HIV type 1 intersubtype A/G recombinant CRF02_AG, which is replication competent in a restricted host range
ZA200300996B (en) Process for the selection of Hiv-1 subtype C isolates, selected Hiv-1 subtype isolates, their genes and modification and derivatives thereof.